Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Terazosin
Drug ID BADD_D02158
Description Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].
Indications and Usage Terazosin is indicated for use in treating symptomatic benign prostatic hyperplasia and hypertension[FDA Label].
Marketing Status approved
ATC Code G04CA03
DrugBank ID DB01162
KEGG ID D08569
MeSH ID C041226
PubChem ID 5401
TTD Drug ID D0P9RF
NDC Product Code 51655-915; 68788-8171; 70518-3211; 70518-3193; 23155-738; 67296-1264; 23155-736; 62135-460; 70518-3272; 62135-459; 23155-735; 23155-737; 71335-9607; 60760-816; 62135-458; 62135-461
UNII 8L5014XET7
Synonyms Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin
Chemical Information
Molecular Formula C19H25N5O4
CAS Registry Number 63590-64-7
SMILES COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000379%
Abnormal dreams19.02.03.001; 17.15.02.001--Not Available
Amblyopia06.02.01.001--Not Available
Anaphylactic reaction24.06.03.006; 10.01.07.001--
Anaphylactic shock24.06.02.004; 10.01.07.002--Not Available
Anaphylactoid reaction24.06.03.007; 10.01.07.003--Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Anxiety19.06.02.002--
Arrhythmia02.03.02.001--Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Arthropathy15.01.01.003--Not Available
Asthenia08.01.01.0010.000167%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000167%Not Available
Bronchitis11.01.09.001; 22.07.01.001--
Bronchospasm10.01.03.012; 22.03.01.004--
Burning sensation17.02.06.001; 08.01.09.029--Not Available
Cardiac failure02.05.01.001--
Cerebrovascular accident24.03.05.001; 17.08.01.0070.000112%
Chest discomfort22.12.02.002; 08.01.08.019; 02.02.02.0090.000245%Not Available
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.011--Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctivitis11.01.06.012; 06.04.01.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages